Monitor the special meeting vote outcome on November 13, 2026. Approval is widely expected given insider support agreements, but failure would trigger cash settlement risk and potential Nasdaq delisting. Also watch for Nasdaq's conditional approval of the listing application, which is required before the meeting.
Price Chart
Executive Summary
Jasper Therapeutics is holding a special meeting on November 13, 2026, to seek stockholder approval for the issuance of common stock upon conversion of preferred stock issued in connection with the Kira Pharmaceuticals acquisition and a concurrent $132M PIPE financing. The filing is a routine procedural step required by Nasdaq listing rules, as the merger and financing have already closed. The outcome is critical for the company's Nasdaq listing compliance and to avoid cash settlement obligations.
Key Facts
- Special meeting on November 13, 2026, to vote on four proposals: Merger Conversion, PIPE Conversion, Director Ratification, and Adjournment.
- The Merger and PIPE Financing have already closed (July 16 and July 20, 2026, respectively).
- Stockholder approval is required under Nasdaq Listing Rules 5635(a), 5635(b), and 5635(d) for the conversion of preferred stock into common stock.
- If approved, up to 604,302,051 shares of common stock could be issued upon conversion of all preferred stock (pre-reverse stock split).
- Pre-transaction Jasper equity holders would hold approximately 6.68%, former Kira equity holders 49.86%, and PIPE investors 43.46% on a fully diluted basis.
- The company received Nasdaq deficiency notices for minimum bid price and stockholders' equity requirements.
- A $30 million CVR milestone payment is contingent on FDA issuing a Priority Review Voucher for briquilimab by December 31, 2028.
- Velan Capital Management LLC and affiliates hold 9.9% of common stock as of the record date.
- Directors and officers representing ~1% of pre-transaction shares have entered into support agreements to vote in favor of proposals 1-3.
- All directors and officers are subject to 180-day lock-up agreements from the closing date.
Financial Impact
The PIPE financing raised $132M in gross proceeds. If stockholder approval is not obtained, the company may be required to cash-settle preferred stock conversions at fair value, which could materially reduce cash available for operations. The pro forma combined cash balance is approximately $142.8M.
Risk Factors
- Failure to obtain stockholder approval could force cash settlement of preferred stock conversions, reducing cash reserves.
- Nasdaq delisting risk if minimum bid price and stockholders' equity requirements are not regained.
- Massive dilution: existing stockholders' ownership would be reduced to ~6.68% of the fully diluted company post-conversion.
- Lock-up agreements restrict insider selling for 180 days, but resale registration for PIPE shares could pressure stock price post-lockup expiration.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEF 14A Filing (Primary) | 0001213900-26-110751 |
| Document: 0001213900-26-110751-index-headers.html | 0001213900-26-110751 |
| Document: 0001213900-26-110751-index.html | 0001213900-26-110751 |
| Document: 0001213900-26-110751.txt | 0001213900-26-110751 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | SC TO-I/A | $0.5054 | awaiting T+5 | — | $0.5189 (+2.67%) |
Oct 20, 2026 7d ago | DEF 14A | $0.4999 $0.5189 | ▲ +3.80% | ▲ +3.72% | $0.5189 (+3.80%) |
Oct 15, 2026 12d ago | 8-K | $0.5321 $0.4956 | ▼ −6.86% | ▼ −5.85% | $0.5189 (−2.48%) |
Oct 15, 2026 12d ago | Press Release | $0.5320 $0.4960 | ▲ +6.77% | ▲ +5.75% | $0.5189 (+2.46%) |
Oct 14, 2026 12d ago | S-3 | $0.5321 $0.4956 | ▲ +6.86% | ▲ +5.85% | $0.5189 (+2.48%) |
Oct 7, 2026 20d ago | 8-K | $0.5697 $0.5010 | ▼ −12.06% | ▼ −11.08% | $0.5189 (−8.92%) |
Oct 7, 2026 20d ago | SC TO-I | $0.5697 $0.5010 | ▼ −12.06% | ▼ −11.08% | $0.5189 (−8.92%) |
Sep 24, 2026 4w ago | 25-NSE | $0.6091 $0.5652 | ▲ +7.21% | ▲ +6.99% | $0.5189 (+14.81%) |
Aug 14, 2026 10w ago | Press Release | $0.7901 $0.7160 | ▼ −9.38% | ▼ −8.01% | $0.5189 (−34.32%) |
Jul 31, 2026 12w ago | 8-K | $0.6300 $0.7095 | ▲ +12.62% | ▲ +9.11% | $0.5189 (−17.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers